Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor.
about
Novel agents for advanced pancreatic cancerA Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationAntitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumorsβ-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.Targeting the insulin-like growth factor-1 receptor in human cancer.Insulin-like growth factor: current concepts and new developments in cancer therapy.IGF-IR and its inhibitors in gastrointestinal carcinomas (Review).Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.A novel role for junctional adhesion molecule-A in tumor proliferation: modulation by an anti-JAM-A monoclonal antibody.Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.Polyubiquitination of insulin-like growth factor I receptor (IGF-IR) activation loop promotes antibody-induced receptor internalization and down-regulation.The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
P2860
Q26787087-E13AB661-2D29-408B-98FF-94A16D7113C8Q30316105-89D61ABA-C681-46EE-9C45-321F595FA4DEQ34387886-70B626CA-18E0-4A2D-A66C-35AD97006FD3Q34431333-2CF4437F-5CD2-4398-8BED-858E3B43FB5DQ34499662-6BFBC363-028C-4776-AC37-13178B3F35C3Q35226507-14F3DC08-B617-45DB-B9BE-D00DEB140C97Q36483910-3CBAFD1F-DC09-44B2-981A-02BA3B330962Q36708178-D22A264F-6992-4F6B-B492-63B386816F0FQ37047067-7FC0D8D3-22CC-41FE-8CA0-CF7B0C318DF2Q38042423-477FA485-F285-4172-B30D-2F282DF265F2Q39250672-6D62E5B8-DAD1-4397-8D73-59B3C59CFD63Q39298958-8157ED4F-BECD-430B-8B15-23489AEFFE77Q39314094-E241A8CC-C3D0-4AC1-9D0B-C01ABB91BE48Q39458884-0863DE4E-08AC-40F4-8F8B-BDE0A317E3ADQ41667670-2AC6FE7B-CF70-4808-B5A2-39918891C665Q47572918-102DEC0D-1580-4BFF-B775-8BE1AA593775Q47582481-229C8AE4-403D-4759-A713-EABDB0CE8C1FQ51531354-E304DAD4-306B-4311-B650-E8BD0B8E4BEB
P2860
Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Molecular mechanisms involved ...... l antibody, to IGF-1 receptor.
@en
Molecular mechanisms involved ...... l antibody, to IGF-1 receptor.
@nl
type
label
Molecular mechanisms involved ...... l antibody, to IGF-1 receptor.
@en
Molecular mechanisms involved ...... l antibody, to IGF-1 receptor.
@nl
prefLabel
Molecular mechanisms involved ...... l antibody, to IGF-1 receptor.
@en
Molecular mechanisms involved ...... l antibody, to IGF-1 receptor.
@nl
P2093
P356
P1476
Molecular mechanisms involved ...... l antibody, to IGF-1 receptor.
@en
P2093
Alexandra Gonzalez
Aline Blaecke
Joëlle Dupont
Liliane Goetsch
Mathilde Fournier
Matthieu Broussas
Nathalie Corvaïa
P304
P356
10.1002/IJC.24186
P577
2009-05-01T00:00:00Z